W El-Matary et al. Inflamm Bowel Dis 2019; 25: 150-5. This retrospective study of 667 children with Crohn’s disease who were prospectively enrolled in an inception study found that 85 (12.7%) had fistulizing perianal disease. The mean infliximab (pre-fourth dose) was 12.7 mcg/mL in responders compared with 5.4 mcg/mL in the active disease group. My take: Higher trough levels are desirable in those with fistulizing disease.
LJT Smits et al. Inflamm Bowel Dis 2019; 25: 172-9. In a prospective cohort with 83 patients with IBD (57 with Crohn’s disease) with at least 2 years of followup, 66% of IBD patients continued CT-P13 after switching from Remicade; two patients developed anti-drug antibodies. The absolute numbers suggest no adverse impact of a single switch to the biosimilar product.
Related blog posts:
- ESPGHAN Position Paper on Biosimilars
- Big Biosimilar Study
- Interchangeability, Immunogenecity and Infliximab Biosimilars
- Biosimilars: “The Horse is out of the barn”
- Pediatric Views on Biosimilars and Interchangeability
- Role of Biosimilars in Inflammatory Bowel Disease | gutsandgrowthEuropean Experience with Biosimilars
- Biosimilars -Position Statement
- FDA approves Amjevita (Humira biosimilar)
- Bioequivalence of Biosimilars
A Tinsley et al. Inflamm Bowel Dis 2019; 25: 369-76. This study documents the increased risk of influenza and increased influenza complications among IBD patients based on a database cohort of 140,480 patients (with and without IBD). The risk of hospitalization was 5.4% in patients with IBD compared with 1.85% in non-IBD patients.
Related blog post: Almost Everybody Needs Flu Shot -IBD Patients at Higher Risk
YY Xu et al. Inflamm Bowel Dis 2019; 25: 261-9. This meta-analysis included 18 nonrandomized controlled trial studies with 1407 patients who received preoperative infliximab and 4589 patients. The authors showed that preoperative infliximab was not associated with any statistically significant differences for the 2 groups for any complications, reoperation, readmission or mortality.
CN Bernstein et al. Inflamm Bowel Dis 2019; 25: 360-8. This study, using population-based administrative health data (Manitoba) found increased burden of psychiatric disorders in IBD: compared with controls the incidence rate ratio for depression was 1.58, for anxiety 1.39, for bipolar disorder 1.82, and for schizophrenia 1.64.
Related blog post: #NASPGHAN17 Psychosocial Problems in Adolescents with IBD